Abstract
Fluoxetine and metformin combined treatment decreases insulin resistance in patients with metabolic syndrome
Highlights
Much of the research on metabolic syndrome (MetS) has focused on the relationships between its cardinal clinical features: insulin resistance (IR), excess abdominal adipose tissue, elevated blood pressure, lipid abnormalities and atherosclerosis [1,2]
Body weight and body mass index are observed to have significantly decreased at end of metformin and fluoxetine treatment (P < 0.05)
It is important to note that blood glucose, HbA1c, HDL-cholesterol and insulin resistance (HOMA) levels had significantly decreased at 20 weeks of treatment with metformin and fluoxetine in these adolescents (P < 0.05) (Table 2)
Summary
Much of the research on metabolic syndrome (MetS) has focused on the relationships between its cardinal clinical features: insulin resistance (IR), excess abdominal adipose tissue, elevated blood pressure, lipid abnormalities and atherosclerosis [1,2]. There is evidence that has linked brain serotonergic activity with peripheral insulin sensitivity [7]. MetS, IR, type 1 and 2 diabetes are conditions that have been shown to exhibit a significant decrease in brain serotonergic neurotransmission [8-11]. Abdominal obesity and type 2 diabetes have been associated with genetic variations of two serotonergic receptors (5-HT2A and 5-HT2C) [12,13]. The brain serotonergic system has several neuroanatomic and functional features that suggest its involvement in the pathophysiology of MetS. Serotonergic activity has been shown to regulate several behaviors, including nutrition, locomotion, reproduction, sleep, pain, aggression and stress response [14], as well as other autonomic functions, such as thermoregulation, cardiovascular control, circadian rhythms and pancreatic function [15-17]
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
